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ABSTRACT Griffithsin (Grft) is an antiviral lectin that has been shown to potently
inhibit HIV-1 by binding high-mannose N-linked glycosylation sites on HIV-1 gp120.
A key factor for Grft potency is glycosylation at N295 of gp120, which is directly ad-
jacent to N332, a target glycan for an entire class of broadly neutralizing antibodies
(bNAbs). Here, we unify previous work on the importance of other glycans to Grft
potency against HIV-1 and Grft’s role in mediating the conformational change of
gp120 by mutating nearly every glycosylation site in gp120. In addition to a signifi-
cant loss of Grft activity by the removal of glycosylation at N295, glycan absence at
N332 or N448 was found to have moderate effects on Grft potency. Interestingly, in
the absence of N295, Grft effectiveness could be improved by a mutation that re-
sults in the glycan at N448 shifting to N446, indicating that the importance of indi-
vidual glycans may be related to their effect on glycosylation density. Grft’s ability to
alter the structure of gp120, exposing the CD4 binding site, correlated with the
presence of glycosylation at N295 only in clade B strains, not clade C strains. We fur-
ther demonstrate that Grft can rescue the activity of the bNAbs PGT121 and PGT126
in the event of a loss or a shift of glycosylation at N332, where the bNAbs suffer a
drastic loss of potency. Despite targeting the same region, Grft in combination with
PGT121 and PGT126 produced additive effects. This indicates that Grft could be an
important combinational therapeutic.
KEYWORDS HIV inhibition, gp120 glycosylation, griffithsin, high mannose,
microbicide
Human immunodeficiency virus type 1 (HIV-1) infects about 2 million people peryear predominantly in developing areas, such as sub-Saharan Africa (1). No vaccine
is yet available, and existing prevention methods, such as daily oral preexposure
prophylaxis, are problematic in these regions in terms of availability and user accept-
ability (2). Microbicides that inhibit HIV-1 infection represent a promising strategy for
the prevention of HIV-1 infection, and formulations that are released by insertable items
that stop the sexual transmission of the virus are envisioned. For instance, intravaginal
rings that release small molecules or antibodies are being developed (3–6), and several
proteins that could potentially be used to prevent infection have recently been
encapsulated into silk fibroin films (7, 8).
Several major types of proteins have been shown to be highly potent HIV-1
inhibitors, including broadly neutralizing antibodies (bNAbs) (9–12), CCR5 binding
proteins (13–16), and lectins (17–20). Each of these types of proteins has moved toward
preclinical or clinical trials with some success (21–27).
Griffithsin (Grft) is among the most promising and potent potential microbicidal
proteins. This lectin can be produced inexpensively in large quantities from tobacco
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leaves (28–31), Escherichia coli (32), and rice endosperm (33) and has been shown to
have low or no toxicity, an unfolding temperature of 78.8°C, stability at pH 4 to 8,
resistance to proteolytic degradation, conservation of potency after incubation at
temperatures of up to 50°C, and safety in mice and macaques when applied topically,
injected, or ingested (7, 25, 28, 34–43). Multiple groups have begun in-human trials (44,
45). Grft is arguably the most potent lectin HIV-1 inhibitor, showing nanomolar to
subnanomolar efficacy against a wide range of HIV-1 strains (18, 28, 39), and has
synergistic activity with currently used HIV-1 antiretroviral drugs, including tenofovir,
maraviroc, enfuvirtide, and the broadly neutralizing antibody (bNAb) VRC01 (46, 47).
Further, due to its ability to bind glycosylated viral surfaces, Grft has been shown to
inhibit other viruses, such as severe acute respiratory syndrome coronavirus (SARS-
CoV), hepatitis C virus (HCV), herpes simplex virus 2 (HSV-2), Japanese encephalitis virus
(JEV), human papillomavirus (HPV), Middle East respiratory syndrome coronavirus
(MERS-CoV), as well as HIV-1 and HIV-2 (48–53).
Grft is a dimer (with 121 amino acids per monomer) that has three saccharide
binding sites per monomer and binds N-linked high-mannose glycans, such as Man-9,
on viral surfaces with a very high affinity (18, 37, 54–56). It has been shown that both
subunits of the Grft dimer are required for potent inhibition of HIV-1, despite the tight
binding by the individual monomeric subunits to glycosylated gp120 (37, 57). This
seeming disconnect between affinity and inhibitory potency has led to the suggestion
that while Grft may inhibit HIV-1 infection in a general way by simply binding to any
high-mannose site(s) on gp120, Grft may be most effective when it binds to specific
regions or when it can cross-link between particular high-mannose sites on gp120,
possibly causing (or preventing) a conformational change in gp120 (57–59). Further
insight into Grft’s mechanism has come from cryo-electron microscopy studies, where
the Bewley group has suggested that Grft can cross-link two separate viruses as part of
its inhibition (59, 60).
gp120 is found on the HIV-1 surface as a trimer (61, 62), with each monomeric unit
having about a dozen relatively conserved high-mannose glycans that can potentially
be bound by Grft (63–65) (Fig. 1A). The high-mannose glycans group together to form
3 main clusters, defined by Balzarini et al. (66), as shown in Fig. 1B to D; cluster 1 is
composed of glycosylation sites (glycosites) N230, N234, and N241, cluster 2 is com-
prised of glycosites N339, N386, and N392, and cluster 3 contains glycosites N295,
N262, N332, and N448. The exact glycosylation pattern varies by strain; relevant strains
are shown in Fig. 2. The gp120 glycosylation site(s) utilized by Grft has been studied by
several groups; the consensus is that glycosylation at N295 of gp120 (in cluster 3) is key
to Grft potency against HIV-1. Several groups showed a correlation between the
presence of the glycosylation sites at N234 and N295 with the very high potency of Grft
against several HIV-1 strains (67, 68). Huang and colleagues, working with different viral
strains, confirmed the importance of glycosylation at N295 of gp120 but showed little
effect of glycosylation at position N234 on the potency of Grft (69), instead pointing to
glycosylation at N448 as being important for Grft potency (69, 70). Cluster 3, sitting at
the base of the V3 loop, has structural significance, as the V3 loop interacts with the
chemokine receptor on the host cell during HIV-1 infection. When Grft binds to cluster
3, it may inhibit the interaction between the V3 loop of gp120 and the chemokine
receptor by forming a physical blockade or by impeding the conformational change
necessary to expose the V3 loop in the open conformation of the HIV-1 trimer (71–74).
Further, cluster 3 includes glycosite N262, which cannot be removed without a com-
plete loss of viral infectivity (75).
The glycosylation of HIV-1 gp120 has become particularly noteworthy due to several
highly potent broadly neutralizing antibodies (bNAbs) that target glycosylation in
gp120 and that are being considered for clinical trials (26, 76–80). One class of these
antibodies targets the glycan at N332, which is found in cluster 3 next to N295. A loss
or a shift of this glycan to N334 upon repetitive bNAb challenge is detrimental to
inhibition by these bNAbs (11, 81–84). bNAbs that bind in this area, such as PGT121,
have a range of effectiveness against these strains (81–83, 85–87). It has been reported
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that Grft is synergistic with the bNAb VRC01, which targets the gp120 CD4 binding site
(47). However, it is not known if Grft can be used in conjunction with bNAbs that target
glycans on gp120 because Grft may compete with these proteins for binding (Fig. 1).
We sought to clarify Grft’s usage of glycosylation sites in cluster 3 by extensively
mutating gp120 from several strains of HIV-1 having distinct properties: two clade B
FIG 1 (A) Structure of the HIV gp160 trimer in the unbound, closed state, i.e., in a state not bound to CD4
or CCR5. This structure of clade B JR-FL includes glycosylation (PDB accession number 5FYK) (118) and
was prepared using the UCSF Chimera program (119, 120). gp120 is shown in khaki, and gp41 is shown
in white. (B to D) gp120 monomers with glycosylation hidden to show the underlying amino acids that
fall into clusters. Glycosylation sites (Asn) are shown in a variety of colors, as labeled in the diagram. (B)
Cluster 1 encompasses the glycans at N230 (orange), N234 (yellow), and N241 (green). (C) Cluster 2
encompasses the glycans at N339 (dark magenta), N386 (dim gray), and N392 (dark slate gray). (D) Cluster
3 encompasses the glycans at N295 (blue), N332 (hot pink), N262 (dark green), and N448 (black). The V3
loop is highlighted in yellow to demonstrate the proximity of the glycans at N295 and N332.
FIG 2 High-mannose glycosylation patterns of HIV strains BaL.01, PVO.4, ZM109, and CAP45. Y, the
presence of a likely high-mannose site. The glycan on CAP45 shown in gray is at position 335 and is most
likely another high-mannose glycan. Cluster 3 is composed of glycans at N262, N295, N332, and N448.
For a full alignment of the sequences, see Fig. 1 posted at http://faculty.ucmerced.edu/pliwang/?page
_id123. High-mannose glycosylation sites were identified through sequence analysis of each strain. The
sequences can be found at www.hiv.lanl.gov.
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strains (strain PVO, clone 4 [PVO.4], and strain BaL.01) that are very sensitive to Grft and
that have essentially all high-mannose sites present, a clade C strain (strain ZM109F.PB4
[ZM109]) that is less sensitive to Grft and that lacks several glycosylation sites, and a
clade C strain (strain CAP45.G3J [CAP45]) that is sensitive to Grft but that does not have
a glycosite at 295. We specifically sought to elucidate the effect that the shifting of
glycans had on Grft potency. The sum of the PVO.4 mutants is the largest collection of
mutants of a single HIV-1 strain to be tested with Grft. We demonstrate Grft’s continued
effectiveness against viral strains where the glycosite at N332 and/or N448 has been
shifted and that Grft is able to remain effective against strains that are resistant to the
bNAbs PGT121 and PGT126. This suggests that Grft could be valuable if used in
combination with bNAbs that are more sensitive to such glycosylation changes. We also
demonstrate that the Grft-mediated conformational change of gp120 appears to be
dependent on the presence of the N295 glycosite in clade B strains but not clade C
strains, indicating distinct mechanisms of Grft binding to gp120 and, therefore, poten-
tially distinct mechanisms of HIV-1 inhibition.
RESULTS
Effect of glycosylation at each site in gp120 on Grft sensitivity in a typical
HIV-1 strain. The glycosylation patterns of several strains of HIV-1 are shown in Fig. 2.
We chose HIV-1 strain PVO.4 to resolve the effect of glycosylation placement on gp120
in relation to Grft sensitivity. This clade B strain is very sensitive to Grft, having a
subnanomolar 50% inhibitory concentration (IC50) of 0.2 0.09 nM, and is also glyco-
sylated at essentially all the sites suggested to be important in Grft inhibition (68–70,
88). In our experiments, each individual high-mannose site in PVO.4 gp120 (except for
N262, due to its importance for structural stability [89]) was removed by mutating the
saccharide-containing Asn to the closely related Gln, which is not glycosylated by
cellular machinery. The single high-mannose site that is not naturally found in PVO.4
(Asn 230) was also mutated to add glycosylation. The sensitivity to Grft inhibition for
each PVO.4 variant was measured in single-round inhibition assays and directly com-
pared to that for the wild-type virus. As shown in Table 1, most individual mutations
had little effect on the ability of Grft to inhibit PVO.4, except for mutation N295Q in
gp120, which led to an 11-fold loss of sensitivity. To a lesser extent (approximately
5-fold), the mutations N448Q and N332Q showed a loss of sensitivity to Grft upon point
mutation.
To determine the combined effect of each of these potentially important glycosy-
lation sites, a double mutation was made in every combination of the sites N295, N448,
and N332, as well as with the site N234, which had previously been observed to
correlate with Grft inhibition (68, 88). Each of these double deletions showed a larger
effect on the ability of Grft to inhibit PVO.4 than each of the single mutations, except
N234Q/N295Q, which was effectively unchanged. The double deletion with the largest
effect, N295Q/N332Q, showed a Grft IC50 43-fold higher than that for the wild-type virus
(Table 1 and Fig. 3). In general, mutants with each combination that included a loss of
the glycosylation site at position 295 showed a relatively high loss of sensitivity to Grft
(Table 1 and Fig. 3), with each lost glycosite at positions 332 and 448 providing some
additive effect. Mutations to remove all three of the proximal glycosylation sites
(N295Q/N332Q/N448Q) in HIV-1 gp120 were made in PVO.4 (Table 1 and Fig. 3),
resulting in an 88-fold loss of sensitivity to Grft. In addition, a triple mutant in which the
glycosite at position 234, as well as the glycosites at positions 295 and 448 (N234Q/
N295Q/N448Q), was removed showed a 28-fold decrease in sensitivity (Table 1).
Removal of more than three glycosylation sites from gp120 resulted in increasingly
poor inhibition by Grft. Deletion of the gp120 glycosylation site N301, in addition to the
existing N295Q/N332Q/N448Q triple mutation, resulted in a 55-fold difference in
inhibition from that of the wild type. The removal of the glycan at position 386, in
conjunction with the triple mutation, revealed a 129-fold difference in inhibition from
that of the wild type. Combining these mutations (N295Q/N301Q/N332Q/N386Q/
N448Q) led to a 126-fold difference in inhibition from that of the wild type. Continuing
Fischer et al. Antimicrobial Agents and Chemotherapy
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in a serial fashion, glycans at Asn392 and then Asn339 were removed, resulting in IC50s
increasing up to 500-fold and 1,000-fold respectively (see Fig. 2 posted at http://faculty
.ucmerced.edu/pliwang/?page_id123). However, mutants with mutations beyond the
triple mutation N295Q/N332Q/N448Q had a decrease in infectivity as well as a loss of
sensitivity to Grft, so the results must be interpreted with caution (see Fig. 2 posted at
the website mentioned above). The low infectivity of the latter mutants made it
unfeasible to continue with serial deletions.
TABLE 1 Inhibition of HIV gp120 variants by Grft
Straina Mutation
Fold differenceb
PcMean SE
PVO.4
Single mutants 197 2.7 0.58 1.6E06
230 2.1 0.56 0.005
234 2.2 0.58 3.7E06
241 3.8 0.91 7.2E09
289 2.8 0.79 0.001
295 11.1 5.83  2.2e16
301 1.4 0.32 6.6E04
332 4.6 1.22 1.4E08
339 2.8 0.59 3.5E11
386 1.5 0.73 0.5
392 1.7 0.35 4.5E05
448 5.1 0.91 9.7E12
Double and triple mutants 234, 295 9.8 3.2 1.7E07
234, 448 6.4 2.4 9.2E10
295, 332 42.9 6.9 2.2E16
295, 448 23.2 7.8 2.7E10
332, 448 35.5 7.1 9.4E07
234, 295, 448 28.2 5.0 3.15E13
295, 332, 448 88.2 10.7 8.1E14
Shift of glycosylation site mutants 332  334 1.3 0.49 0.2
448  446 1.7 0.79 0.04
295, 332  334 8.0 2.3 8.1E09
295, 448  446 3.2 0.9 6.6E09
332  334, 448 6.6 2.7 1.1E07
332, 448  446 10.2 3.3 1.4E11
332  334, 448  446 5.4 3.7 8.8E05
295, 332  334, 448 21.2 18.0 3.8E05
295, 332, 448  446 29.4 11.5 4.3E09
295, 332 334, 448 446 21.5 4.7 2.8E06
BaL.01 295 14.1 1.9 1.0E10
332 2.1 0.6 0.002
448 1.0 0.3 0.57
ZM109 234 10.2 2.6 1.0E11
295 52.9 12.6 8.1E13
332 1.0 0.3 0.8
334 1.4 0.2 0.005
446 1.2 0.1 0.03
448 4.3 1.2 1.4E11
234, 295 157 66 2.6E16
234, 446 20.6 6.3 1.1E11
CAP45 234 1.2 0.3 0.4
295 3.2 1.2 7.3E10
332 3.2 1.2 4.7E08
334 2.3 0.9 1.1E03
446 2.0 0.9 1.5E03
448 1.3 0.6 0.1
aThe Gfrt IC50 for wild-type strains PVO.4, BaL.01, ZM109, and CAP45 are 0.2  0.09, 0.26  0.08, 26.9  6.2, and 0.54  0.24 nM (standard error), respectively.
bMean is the average of triplicate data replicated a minimum of three times. A plus sign indicates that Grft inhibits the wild-type virus better than the mutant virus. A
minus sign indicates that Grft inhibits the wild-type virus less well than the mutant virus (the mutant is more sensitive to Grft).
cP values were determined by an analysis of variance with the Bonferroni correction.
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Several point mutations in gp120 in the commonly used HIV-1 strain BaL.01 were
also carried out to remove the glycosylation at glycosylation cluster 3 (66). As expected,
removal of glycosylation at position 295 showed the largest effect. Little effect was seen
when glycosylation at either position 332 or position 448 was individually removed
(Table 1). This finding differs from the results of Huang et al. (69), who observed a loss
of potency of Grft when gp120 was mutated to remove glycosylation at position 448
in this strain. This disparity may be due to differences in the IC50 assay techniques used
(see Fig. 5 posted at the website mentioned above).
Shifting gp120 glycosylation sites around N295 has little effect on sensitivity
to Grft. The N332 glycosylation site was further explored due to the importance of the
glycan at this site as a target for broadly neutralizing antibodies (81–83, 85–87). As
shown in Table 1, Grft maintained potency against PVO.4 when glycosite N332 was
shifted to position 334. An analysis of thousands of published HIV-1 strains (245 clade
A, 2,231 clade B, and 1,449 clade C strains) in the HIV-1 sequence database was carried
out, looking at the conservation of each high-mannose glycan and the frequency of
shifts occurring at each site. The glycans in cluster 3 showed the most movement in
their location. Approximately 12% of all HIV-1 strains have a glycan located at N334
(referred to here as the N332  N334 shift; see Fig. 3 posted at the website mentioned
above). The other most common relocation is found primarily in clade C strains: 26% of
clade C strains do not have glycosylation at position 448, and 72% of those exhibit a
glycan at N446 instead (referred to here as the N448  N446 shift; see Fig. 3C posted
at the website mentioned above). Since removal of glycosite N448 in strain PVO.4
showed a clear decrease in Grft potency, we evaluated the N448  N446 shift as well.
Table 1 shows that shifting the glycosylation site in PVO.4 (N448  N446) did not have
a significant effect on Grft sensitivity.
We then investigated individual shift mutations (N332  N334, N448  N446) in
combination with glycan deletions at other sites in cluster 3, N295Q, N332Q, and
FIG 3 Grft inhibition against PVO.4 gp120 mutants. Each individual mutation is represented by a color,
as follows: red, N295; yellow, N332; blue, N448; orange, N332 N334; green, N448 N446. A minus sign
indicates that glycan has been removed. The greater than sign () indicates that glycan has been shifted.
These colors are combined to represent combinational mutants. Circles indicate single mutants, dia-
monds indicate double mutants, and squares indicate triple mutants. Glycan deletion mutants were
made by mutating the Asn to Gln. For statistical analysis, see Table 1 posted at http://faculty
.ucmerced.edu/pliwang/?page_id123.
Fischer et al. Antimicrobial Agents and Chemotherapy
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N448Q (see Table 1 for the IC50s and Fig. 3 for a graphical representation of the results;
see Table 1 at http://faculty.ucmerced.edu/pliwang/?page_id123 for the results of
statistical analysis). In addition, two mutants that had both shifts, one in the presence
and the other in the absence of glycosite N295, were generated (Table 1 and Fig. 3).
Overall, the N332  N334 shift had little effect on Grft potency. In general, the N448 
N446 shift also had little effect, with the notable exception that this shift increased the
sensitivity of the virus to Grft (lowered the IC50) when the virus also lacked the glycan
at position 295.
Effect of glycosylation on HIV-1 strain ZM109F.PB4. While Grft has been shown
to be effective against strains from all clades tested, it has shown variable effectiveness
against strains from clade C. This has been ascribed to differences in glycosylation
patterns across clades, particularly the lack of glycosylation site at position 295 for 79%
of clade C strains (see Fig. 3C posted at the website mentioned above). Among the
strains tested, ZM109 had the lowest sensitivity to Grft with an IC50 of 27 6 nM. This
strain lacks the glycosylation site at positions 234 and 295 and also exhibits the N332
 N334 shift in glycosylation (90) (Fig. 2). To investigate the role of glycosylation in
sensitivity to Grft, several mutations were carried out, focusing on the critical glycosy-
lation cluster comprised of N295/N33(2)4/N448. As shown in Table 1, placing a glycan
at position 332 or removing one at position 334 has little effect on sensitivity to Grft,
while adding a glycosylation site at position 295 dramatically improved sensitivity to
Grft, with a 53-fold reduction in the IC50.
Interestingly, when the glycosylation site at position N448 in ZM109 gp120 is shifted
to position 446 in the virus (which naturally lacks glycosylation at position 295), a 4-fold
increase in sensitivity to Grft was observed (Table 1). Similar to the results with strain
PVO.4, this indicates that a shift of glycosylation to the 446 position may be able to
partially rescue the loss of the glycosylation site at position 295 in terms of Grft action
(Fig. 4).
The glycosylation site at position N234 in gp120 has also been described to be
important in some strains, despite this site being in cluster 1 and distal to the critical
cluster 3 (Fig. 1) (66, 68). Although ZM109 was not mentioned in that study, when a
glycosylation site is added at position 234, a 10-fold increase in sensitivity to Grft was
observed. Most striking was the finding that when glycosylation was enabled at both
position 234 and position 295, a 157-fold increase in Grft sensitivity was observed
(Table 1).
Effect of glycosylation on gp120 in CAP45.G3J, a Grft-sensitive strain that
naturally lacks glycosylation at 295. Grft is highly potent across many strains of
HIV-1, including some that naturally lack the glycosylation site at position 295. One
FIG 4 A visual representation of how the shift of a glycan from N448 to N446 in the absence of a glycan
at N295 may lead to a higher glycan density and, therefore, a better binding environment for Grft. (Left)
gp120 monomer, with the relevant glycan sites in cluster 3 (N295, N332, N448) being indicated. (Right)
gp120 with the amino acid at position 446 (red) to show its proximity to cluster 3 (circled in red) if it is
mutated to Asn to become a glycosite. The structure has PDB accession number 5FYK (118) and was
modeled using the UCSF Chimera program (119, 120).
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such strain is CAP45.G3J (which is referred to here as CAP45), a clade C virus that lacks
glycosylation sites at positions 295, 332, and 392 and yet is inhibited by Grft with an
IC50 of 0.54 0.23 nM. To investigate the role of glycosylation in such a strain, we made
mutations in the important glycan cluster 3. When the glycosylation site at N295 was
added back to this gp120, sensitivity to Grft was moderately improved by a factor of
3.2-fold (Table 1). The other two glycans in cluster 3 are naturally in the shifted
positions, N334 and N446 (Fig. 2). Returning the glycan at N334 back to its canonical
site at N332 or deleting it entirely also moderately decreased the IC50. Movement of a
glycosite to N448 produced no difference in sensitivity from that of the wild type,
whereas deletion of the glycan at that location was one of the few mutations that
caused a slight increase in the Grft IC50.
Grft is compatible with broadly neutralizing antibodies targeting glycan at
gp120 N332. We next investigated the potential of Grft as a combinational therapy
with bNAbs. It has previously been shown that Grft is synergistic with the bNAb VRC01,
which targets a separate area of gp120 (the CD4 binding site), so we sought to
determine if Grft is compatible with another major class of bNAbs which target the
glycan at N332 and which may therefore be antagonistic with Grft. As shown in Fig. 5,
in strains in which the activity of Grft is relatively weak, the activities of PGT121 and
PGT126 are potent, and vice versa. We then analyzed the HIV-1 neutralization activity
of Grft when it was used in combination with the two bNAbs in a constant 1:1 IC50 ratio.
Grft was able to rescue the activity when bNAbs became ineffective after the loss or the
shift of the glycan at N332 (Fig. 6B and C and 7B and D). The effects of the combinations
ranged from synergistic to mildly antagonistic, with combination index (CI) values
ranging from 0.64 to 1.48 (Fig. 6 and 7).
Conformational changes induced by griffithsin. It was previously demonstrated
that the naturally occurring presence of glycosite 295 in some strains of gp120 seemed
to be a strong determinant of the ability of Grft to induce a conformational change in
gp120, exposing the CD4 binding site, and that this correlated well with inhibition
potency (57, 58). These experiments used virion capture by a conformationally sensitive
antibody (the b12 antibody) after incubation of the virion with Grft. We sought to
confirm this finding using the same virion capture assay against wild-type and mutated
viruses (Fig. 8). Clade B strains PVO.4 and BaL.01 showed a significant decrease in CD4
site exposure upon incubation with Grft when glycosite N295 was removed (Fig. 8).
FIG 5 Grft and bNAbs PGT121 and PGT126 have complementary activity against a range of viral variants.
IC50 values for Grft, PGT121, and PGT126 in single-round infection assays against various strains and
mutants involving glycosylation at N332 and N295 of gp120 are shown. Wild-type strain CAP45 naturally
has N334; therefore, N332 indicates a shift of the glycan to N332. Solid bars indicate the presence of
the glycan, and slashed bars indicate the absence of the glycan (also labeled on the x axis, where a plus
sign indicates the presence of a glycan and a minus sign indicates the absence of a glycan at that site).
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However, clade C viruses did not show a correlation between the presence of glyco-
sylation at position 295 in gp120 and exposure of the CD4 binding site upon incubation
with Grft (Fig. 8), despite the previous results showing that the addition of glycosite
N295 to ZM109 did increase its sensitivity to Grft (Table 1).
DISCUSSION
In the fight against HIV-1, the use of the same drug(s) in both HIV-1 prevention and
treatment leads to concerns about the development of viral resistance. Therefore, it is
critical to develop other means of HIV-1 prevention that can be cheaply produced
(28–30, 32, 33) in a sustained-release, heat-stable formulation (3–7, 91, 92) so that they
can be easily distributed in sub-Saharan Africa. The lectin Grft is a strong candidate for
use in such a prevention technique. A successful microbicide must be effective against
a wide range of HIV-1 strains, so it is imperative to understand the components of Grft
inhibition. Grft potency is independent of coreceptor usage by the virus; however, Grft’s
direct binding to high-mannose glycans on gp120 necessitates the determination of
which glycosylation sites are involved in Grft inhibition, with the goal of optimizing Grft
usage either alone or in combination with other inhibitors, such as bNAbs, that have
separate modes of action (46, 93).
It has previously been reported that glycosylation at N295 on gp120 is critical for the
potency of Grft and other lectins against HIV-1 (35, 67–69, 88, 94, 95). However, there
is disagreement about the importance of glycosylation at other sites, with some reports
demonstrating that glycosylation at the sites N448, N339, and N234 is also important
for Grft inhibition (67–70). Our work provides detailed and comprehensive data on how
glycosylation at various sites on gp120 affects Grft potency. In so doing, we also gain
insight into the mechanism of Grft action against HIV-1 entry. In the typical strain PVO.4,
each high-mannose site was individually eliminated through mutation. It was found
that the most important individual site was, as expected, N295; moderate effects were
FIG 6 Activity of the combination of Grft and PGT121 against select wild-type and mutant strains of HIV.
(A to E) Dose-response curves of Grft and PGT121 singly and in combination against wild-type HIV strains
or strains with the indicated mutations to demonstrate Grft’s ability to rescue in the absence or a shift
of a glycan at N332 without antagonistic effects. The combinations were tested by dilution of Grft and
PGT121 at a fixed 1:1 ratio proportional to their IC50s. Relatively high starting concentrations were serially
diluted to get a dose-response curve. Starting concentrations of Grft were as follows: 2 nM for the PVO.4
wild type (Wt) and PVO.4 with a glycan shift to position 334 (334), 12 nM for PVO.4 with a deletion of
the glycan at 332 (332), 5.4 nM for the CAP45 wild type, and 3.4 nM for CAP45 with a glycan shifted
back to 332 (332). The starting concentrations of PGT121 were as follows: 60 nM for all PVO.4 variants,
107 nM for the CAP45 wild type, and 20 nM for CAP45 with a glycan shifted back to 332.
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also seen upon individual elimination of glycosites N332 and N448 of gp120. Grft
sensitivity to mutations at other high-mannose sites diminished with the distance from
the center of the high-mannose patch at cluster 3 (Table 1). Combinations of mutations
at this glycan cluster 3 site impaired Grft potency, with the mutant with the triple
mutations N295Q/N332Q/N448Q showing an 88-fold reduction in sensitivity. The ef-
fectiveness of Grft was also tested against two strains that naturally lack glycosylation
at gp120 position 295. One of these strains is less sensitive to Grft (ZM109), and the
other is quite sensitive to Grft (CAP45). It was found that adding a glycosylation site at
position 295 did increase the sensitivity of both strains to Grft, although the effect was
much larger for ZM109 (Table 1).
These results suggest that Grft potency and the importance of glycosylation at N295
are at least partially due to the density of the glycan cluster. The location of N295 places
it near the center of the high-mannose patch of gp120 (96, 97). Previous research has
shown that the N295 site in gp120 stabilizes the high-mannose patch and that the loss
of glycosylation at this site leads to increased enzymatic processing of the glycans in
the area (98, 99) (Fig. 4). This would explain the disparate results obtained by other
researchers, since the glycan locations in each strain would have slightly different
impacts on glycan processing based on the gp120 conformation. Thermodynamic
studies have shown that Grft binds more tightly to a saccharide that is closely related
to Man-9 than to one that more resembles a processed site, such as Man-5 (37). Also,
glycosite N295 is placed at the base of the V3 loop, which means that binding to this
site would likely allow Grft to inhibit the gp120 interaction with CCR5, possibly through
hindrance of a gp120 conformational change or a CCR5-V3 loop interaction. This
reasoning is corroborated by the rescue of Grft potency by the glycan shift from N448
to N446, in the absence of N295, in strains PVO.4 and ZM109 (Table 1 and Fig. 3). The
presence of a glycan at N446 may fill the hole in the high-mannose patch created by
FIG 7 Activity of the combination of Grft and PGT126 against select strains and mutations of HIV. (A to
E) Dose-response curves of Grft and PGT126 singly and in combination against wild-type HIV strains or
strains with the indicated mutations to demonstrate Grft’s ability to rescue in the absence or shift of a
glycan at N332 without antagonistic effects. The combinations were tested by dilution of Grft and
PGT126 at a fixed 1:1 ratio proportional to their IC50s. Relatively high starting concentrations were serially
diluted to get a dose-response curve. The starting concentrations of Grft were as follows: 1 nM for the
PVO.4 wild type (Wt), 2 nM for PVO.4 with a glycan shift to 334 (334), 12 nM for PVO.4 with a deletion
of the glycan at 332 (332), 5.4 nM for the CAP45 wild type. and 3.4 nM for CAP45 with a glycan shifted
back to 332 (332). Starting concentrations of PGT126 were as follows: 11 nM for the PVO.4 wild type,
60 nM for PVO.4 with the glycan shifted to position 334 or removed from position 332, 60 nM for the
CAP45 wild type, and 120 nM for CAP45 with a glycan shifted back to position 332.
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the loss of N295 and so facilitate Grft binding in an orientation and location similar to
those when a glycan is present at N295 (Fig. 4). CAP45, which is sensitive to Grft and
which is not glycosylated at position 295, may retain a high-density glycan patch in
cluster 3 by virtue of having an additional, nonconserved glycan in the region at N335,
which is located near the center of the glycan cluster 3 (Fig. 2). This additional gly-
can may help to maintain the density of the glycan patch, thereby minimizing glycan
processing. Further mutational studies in conjunction with analysis of the glycan
composition by mass spectrometry would substantiate these hypotheses.
The glycosylation at site N332 in HIV-1 gp120 is particularly important in the
prevention of HIV-1 infection because it provides the binding site for several highly
potent bNAbs which have been proposed to be possible microbicides or injectable
therapies (85, 86). In some viral strains, the natural glycosite is at N332, while others
show a glycan at N334 instead. A range of effectiveness is observed for bNAbs that bind
this area, with the antibodies retaining potency against some strains while losing
efficacy against others (81, 84, 85). We show that Grft is largely insensitive to shifts in
the glycosite at either position 332 or position 448, indicating that Grft could be used
to complement bNAbs as part of a plan for the prevention of HIV-1 infection (Table 1
and Fig. 2). Indeed, we found that bNAbs complement the activity of Grft against a
variety of strains: the combination of PGT121 or PGT126 with Grft resulted in potent
inhibition of HIV-1, regardless of the presence of glycosylation at site N295 or N332,
making such a combination valuable for inhibiting a wide range of viral strains. Grft was
able to rescue inhibition when the bNAbs lost potency after the shift or removal of the
glycan at N332, and the bNAbs had minimal sensitivity to the loss of N295. Despite their
preference for neighboring glycans (and, therefore, the possibility of antagonism
between Grft and the bNAbs), Grft displayed primarily additive effects when combined
with these bNAbs. There was only one instance (the return of a glycan at N332 in
CAP45) where Grft and PGT121 showed mildly antagonistic effects when combined.
Since only the full removal (of primarily N295) and not the shifting of glycans inhibits
Grft potency, Grft’s addition to any combinational therapy appears to be consistently
beneficial, as Grft can rescue in instances where shifting glycans negate antibody
FIG 8 Grft mediates CD4 binding site exposure in clade B viruses. A virion capture assay using MAb b12
to capture HIV virions with an exposed CD4 binding site was performed. Filled circles indicate samples
with 4 nM Grft. Open circles indicate samples with 0 nM Grft. PVO.4 and BaL.01 naturally have N295, while
CAP45 and ZM109 do not. Colored asterisks (found over PVO.4 WT, PVO.4 -295, BaL.01 Wt, and
Cap45 295) indicate a comparison of filled versus open circles and that the mean for the samples with
4 nM Grft was significantly (P 0.0001) different from that for the samples with no Grft. Black asterisks
indicate a comparison between the wild-type and mutant of a single strain, showing where the results
for the wild-type and mutant samples at 4 nM Grft for a single strain were significantly different from
each other (P 0.0001). Significance was calculated using a one-way analysis of variance with a post hoc
pairwise t test and the Bonferroni correction.
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potency. It has previously been shown that viral escape from Grft primarily requires the
complete removal of glycans (88), which would increase viral susceptibility to the
immune system.
Grft is able to induce a conformational change in gp120 that is generally correlated
to inhibitory potency, increasing gp120 binding to the conformationally sensitive
antibody b12 (57, 58). In the current work, we studied this conformational change by
making mutations to a set of viruses, allowing a direct comparison in the presence or
the absence of particular glycosites in each virus rather than a comparison of separate
strains and inference of a correlation. We show that for clade B strains, the conforma-
tional change mediated by Grft is dependent on the presence of the glycosylation at
position 295 and is correlated with inhibitory potency. However, the clade C strains
CAP45 and ZM109 did not show a significant difference in conformational change
regardless of the presence or absence of glycosylation at position 295, although they
have different properties. CAP45 may be in a b12-binding conformation regardless of
the presence of Grft (Fig. 8), and ZM109 shows little conformational change regardless
of the presence of glycosylation at the N295 site, but the presence of glycosylation at
N295 dramatically enhances its sensitivity to Grft. Taken together, these data suggest
that Grft is capable of binding clade B viruses differently than clade C viruses. However,
the link between conformational change and inhibition of clade B viruses may be an
instance of correlation and not causation.
Overall, this work delineates several modes of interaction between Grft and gp120
and shows that vulnerabilities in Grft inhibition are complementary to vulnerabilities in
some bNAbs that bind to glycosylation sites on gp120, such as PGT121 and PGT126. A
combination of Grft with either bNAb has additive effects, and Grft can fully rescue
inhibition in the presence of glycan shifts in gp120 that inactivate these bNAbs.
Therefore, Grft is a suitable candidate for combinational therapies with bNAbs.
MATERIALS AND METHODS
Protein production and purification. Plasmids containing the Grft gene with an associated
N-terminal histidine tag were transformed into Escherichia coli BL21(DE3) (Novagen) competent cells and
expressed in minimal medium with 15NH4Cl as the sole nitrogen source. After induction with isopropyl
-D-1-thiogalactopyranoside (IPTG), the cells were incubated at 22°C for 16 h. Once harvested, the
pelleted cells were resuspended in 6 M guanidine hydrochloride, 200 mM NaCl, and 50 mM Tris (pH 8.0),
which allowed complete solubilization of the proteins from both the inclusion and the supernatant upon
cell disruption. The resulting solution was passed through a French press three times at 16,000 lb/in2 and
then centrifuged at 27,000 g for 1 h. The supernatant was loaded onto a nickel chelating column
(Qiagen, Hilden, Germany) that had been equilibrated with the same resuspension buffer. The flow-
through was collected and rerun over the column. The column was washed with the resuspension buffer
and then a wash buffer with 6 M guanidine hydrochloride, 200 mM NaCl, and 20 mM NaPi (pH 7.2). Grft
was eluted using 6 M guanidine hydrochloride, 200 mM NaCl, and 20 mM sodium acetate (pH 4.0) and
then added dropwise to a refolding buffer (200 mM NaCl, 1 mM EDTA, 550 mM arginine hydrochloride,
60 mM Tris, pH 8.0) and allowed to stir overnight at 4°C. The solution was then dialyzed in 4 liters 200 mM
NaCl and Tris (pH 8.0) for 5 h at 4°C and then transferred to new dialysis buffer (4 liters), and the mixture
was stirred at 4°C overnight. The protein solution was then transferred to 4 liters of a low-salt dialysis
buffer (80 mM NaCl, 20 mM Tris, pH 8.0). The protein was finally purified on a C4 reversed-phase
chromatography column (Vydac, Hesperia, CA) and lyophilized in a Labconco freeze-dry system for
long-term storage. All samples were analyzed by sodium dodecyl sulfate-polyacrylamide gel electropho-
resis (SDS-PAGE) at each step of purification to confirm the proper size of the Grft construct. Nuclear
magnetic resonance (NMR) spectroscopy was used to determine that griffithsin was properly folded, as
described previously (57).
Viruses and reagents. Viral plasmids containing the env gene from HIV-1 were obtained from the
AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, NIH, as follows: PVO, clone 4,
strain SVPB11 (referred to as PVO.4), from David Montefiori and Feng Gao (100); ZM109F.PB4, strain
SVPC13 (referred to as ZM109), from C. A. Derdeyn and E. Hunter (101); CAP45.2.00.G3, strain SVPC16
(referred to as CAP45), from L. Morris, K. Mlisana, and D. Montefiori (102); and HIV-1 clone BaL.01, catalog
number 11445 (referred to as BaL.01), from J. R. Mascola (103). The viral genome pSG3ΔEnv, used to make
single-round virus, was from John C. Kappes and Xiaoyun Wu (104, 105). Sequencing primers for all
viruses were generated using the Integrated DNA Technologies OligoAnalyzer (https://www.idtdna.com/
calc/analyzer) and ordered from ELIM Biopharm (https://www.elimbio.com/services/oligo-synthesis/).
TZM-bl cells were obtained through the AIDS Research and Reference Reagent Program, Division of AIDS,
NIAID, NIH, from John C. Kappes, Xiaoyun Wu, and Tranzyme Inc. (104, 106–109). 239-FT cells were
obtained from Invitrogen (110–112). Both cell lines were cultured in Dulbecco modified Eagle medium
(DMEM) containing 10% fetal bovine serum, 25 mM HEPES with penicillin-streptomycin or Geneticin,
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respectively. The anti-HIV-1 gp120 monoclonal antibody (MAb; IgG1 b12) was obtained through the AIDS
Research and Reference Reagent Program, Division of AIDS, NIAID, NIH, from Dennis Burton and Carlos
Barbas (113–116).
Generation of mutant env-pseudotyped virus DNA. All mutants were generated by a 2-step PCR
using reagents from New England Biolabs Inc. (MA, USA). Step 1 of the PCR used Phusion polymerase to
generate fragments of the gene overlapping at the site of the mutational primer, using the protocol
suggested by New England Biolabs Inc. Step 2 of the PCR combined the two fragments without primers
for 10 cycles, and then an additional 30 cycles were run under normal conditions (the end primers of the
gene were added). The products of both steps of PCR were purified using a GeneJET PCR purification kit
(Thermo Scientific, MA, USA). DNA was digested with restriction enzymes from New England Biolabs (MA,
USA) and then ligated into pCDNA3.1 (for strains PVO.4, BaL.01, and CAP45) or pCR3.1 (for strain ZM109).
The presence of mutations was confirmed by DNA sequencing.
Generation of env-pseudotyped single-round virus. 293-FT cells were grown in DMEM with
500 g/ml Geneticin and cotransfected with 10 ng of the desired envelope plasmid and 10 ng of the
pSG3ΔEnv plasmid using the X-tremeGENE HP DNA transfection reagent (Roche/Sigma-Aldrich, St. Louis,
MO, USA). Transfected cells grew for 24 to 48 h, depending on the strain. The supernatant was collected,
centrifuged, and then filtered through 0.45-m-pore-size membranes. Viral stocks were stored in
low-binding tubes at 80°C.
Single-cycle neutralization assay (TZM-bl cell assay). On day 1, 104 TZM-bl cells (grown in DMEM
with 1% penicillin-streptomycin) were seeded into a 96-well plate and allowed to incubate at 37°C for 18
to 20 h. On day 2, the medium was changed at 1 h 40 min before the time of the assay and added to
a final volume of 50 l per well. A dilution series of Grft, tailored to the strain and mutation of virus to
be added, was made in phosphate-buffered saline (PBS), and 20 l was added to the wells (or 20 l of
PBS for controls). Thirty microliters of single-round virus (at a dilution that would result in a read at an
absorbance of 570 nm at approximately 40 min) was added 20 min later, with three rows of the plate
being used for the mutated virus and three rows being used for the wild type of the virus being tested.
The wells on the edge of the plate were not used due to evaporation effects. On day 3, after 18 to 20 h,
the medium was changed and the cells were allowed to incubate for 48 h. On day 5, the cells were lysed
using 0.5% NP-40 in PBS, and a substrate solution was added (20 mM KCl, 100 mM 2-mercaptoethanol,
8.3 mM chlorophenol red--D-galactopyranoside [Calbiochem] in PBS). The absorbance signal was mea-
sured at 570 nm and 630 nm when the reading at 570 nm was approximately 2. The ratio of the signal
at 570 nm over that at 630 nm was calculated and compared to the ratio for the controls to determine
the percent infection for each well. The 50% inhibitory concentration was determined using a linear
equation fitted between the two data points surrounding 50% inhibition for each row, and the three
values were averaged for a final IC50. All mutants were tested in triplicate three times or more. After
approximately 2 years of data collection, the average IC50 for all strains dropped by approximately 2-fold.
To our best determination, this was caused by a change in the composition of the medium from the
commercial source. However, the ratios between the wild type and the mutants remained consistent (see
Fig. 4 posted at http://faculty.ucmerced.edu/pliwang/?page_id123); therefore, the data are presented
as the fold difference from the wild type. The data were plotted using Microsoft Excel software. For
synergy studies, combinations of Grft with bNAbs PGT121 and PGT126 were tested by use of a dilution
series at a fixed 1:1 ratio proportional to their IC50s. The combination index (CI) was calculated using
CompuSyn software, based on the equations of Chou and Talalay (117). The data were plotted using
Microsoft Excel software, with curve fit equation generated in Matlab software.
p24 ELISA and relative infectivity. Virus samples were diluted to a final volume of 225 l, and then
25 l of 5% Triton X-100 was added to the samples. The samples were then vortexed for 20 s, before
being incubated at 37°C for 30 min. The amount of p24 was measured using a human immunodeficiency
virus type 1 (HIV-1) p24/capsid protein p24 enzyme-linked immunosorbent assay (ELISA) kit from
Sinobiological (Beijing, China) according to the manufacturer’s instructions. Relative infectivity was
determined by a single-cycle neutralization assay, with all viral dilutions being normalized by the p24
concentrations. The results were calculated using a four-parameter logistic curve on the website for
MyAssays analysis software.
Virion capture ELISA. Exposure of the gp120 CD4 binding site was measured as described
previously by the Morris and colleagues (68) and LiWang and colleagues (57). Briefly, high-binding
96-well flat-bottomed plates (Thermo Scientific, MA, USA) were coated overnight at 4°C with 1 g/well
of MAb b12 in PBS. On day 2, the plate was washed and blocked with bovine serum albumin. Pseudovirus
samples were preincubated with Grft at 4 nM and 20 nM and a medium-only control for 1 h at 37°C and
then added to the b12-coated plate and incubated for another 2 h at 37°C. Then, the plate was washed,
and bound virus was lysed with 150 l 0.5% Triton X-100. One hundred microliters of virus lysate was
transferred to a human immunodeficiency virus type 1 (HIV-1) p24/capsid protein p24 ELISA kit from
Sinobiological (Beijing, China) and tested according to the manufacturer’s instructions.
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